Astec Lifesciences, once Godrej Agrovet’s shiny “specialty chemicals ka startup baccha,” has now become the class topper in negative returns. Stock at ₹902, market cap ₹2,011 Cr, sales stuck at ₹403 Cr, but losses ballooning to -₹128 Cr FY25. ROE? A glorious -45%. Three CFOs in 8 months, tax notices, debt at ₹555 Cr, and still trading at 8.6× book value. Investor patience is thinner than a pesticide spray.
2. Introduction
Back in the good old FY18–FY22 days, Astec was riding high. A B2B-only model, triazole fungicide exports, and custom synthesis projects for Japanese/European clients made it a mini-PI Industries aspirant. Godrej Agrovet (65% → 72% holding) pushed it as their crown jewel in chemicals.
Then, the fairy tale ended. Sales peaked at ₹677 Cr FY22, and since then revenues have dropped like pesticide-sprayed locusts: ₹628 Cr (FY23), ₹458 Cr (FY24), and ₹403 Cr (FY25). Meanwhile, costs ballooned, margins collapsed (OPM from +23% FY22 to -8% FY25), and interest load rose as debt doubled.
To add masala, the CFO chair turned into a game of musical chairs: 3 CFOs between 2022–23. That’s never a sign of smooth sailing. And now SEBI disclosures + ₹41 Cr tax demand notice = full drama.
3. Business Model (WTF Do They Even Do?)
Astec makes active ingredients and intermediates for global agrochemical firms. Think of it as the behind-the-scenes lab partner for multinationals.
Enterprise business (74%): Manufacturing own technicals—fungicides, herbicides, insecticides.
Contract manufacturing (26%): Custom synthesis projects for Europe, Japan, US clients.
Geography: 61% exports, 39% domestic. Facilities: 4 plants, one herbicide greenfield site, aiming for Zero Liquid Discharge (ZLD). R&D: Adi Godrej Center for Chemical R&D, opened FY23 to woo CDMO clients.
Narrative: They wanted to be “India’s CDMO play in agrochemicals,” like PI Industries. Reality check? They became “India’s loss-making CDMO intern.”
4. Financials Overview
Quarterly Snapshot (Jun ’25 vs YoY & QoQ):
Source table
Metric
Jun ’25
Jun ’24
Mar ’25
YoY %
QoQ %
Revenue
₹91 Cr
₹69 Cr
₹120 Cr
+31%
-24%
EBITDA
-₹11 Cr
-₹46 Cr
₹6 Cr
+76%
N.A.
PAT
-₹33 Cr
-₹40 Cr
-₹16 Cr
+18%
N.A.
EPS (₹)
-14.8
-17.7
-7.2
+16%
N.A.
Annualised EPS: negative, so P/E = not meaningful. Sales growth YoY looks okay (base effect), but profitability is still poisoned.
5. Valuation (Fair Value RANGE only)
P/E method: Not applicable, EPS negative.
EV/EBITDA: EV ₹2,563 Cr; EBITDA FY25 -₹31 Cr → meaningless.
